Molecular Radiotherapy Comes of Age.

[1]  B. de Keizer,et al.  Current Status and Future Direction of Hepatic Radioembolisation. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[2]  I. Murray,et al.  Systemic Radiotherapy of Bone Metastases With Radionuclides. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  E. Miles,et al.  Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  M. Beasley,et al.  Prospects for Personalised Treatment of Patients with Radioiodine-avid Locally Recurrent or Metastatic Thyroid Cancer. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  M. Bardiès,et al.  Scientific Developments in Imaging and Dosimetry for Molecular Radiotherapy. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  J. Tran-Gia,et al.  Multicentre Trials on Standardised Quantitative Imaging and Dosimetry for Radionuclide Therapies. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  J. Buscombe.  The Future of Molecular Radiotherapy Services in the UK. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  F. Verburg,et al.  Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[9]  M. Gaze,et al.  Paediatric Molecular Radiotherapy: Challenges and Opportunities. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  A. Sundlöv,et al.  Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[11]  M. McDevitt,et al.  Radiopharmaceutical therapy in cancer: clinical advances and challenges , 2020, Nature Reviews Drug Discovery.

[12]  W E Bolch,et al.  ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals , 2019, Annals of the ICRP.

[13]  D. McGowan,et al.  Eighty per cent more patients in 10 years of UK molecular radiotherapy: Internal Dosimetry Users Group survey results from 2007 to 2017 , 2019, Nuclear medicine communications.

[14]  E. Visser,et al.  From fixed activities to personalized treatments in radionuclide therapy: lost in translation? , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  W. Oyen,et al.  Dosimetry in clinical radionuclide therapy: the devil is in the detail , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  V. R. McCready,et al.  Radioiodine – the success story of Nuclear Medicine , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  Michael Lassmann,et al.  The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Glenn D. Flux,et al.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Giampiero Tosi,et al.  Dosimetry in Peptide radionuclide receptor therapy: a review. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  A. Sundl.  Peptide Receptor Radionuclide Therapy e Prospects for Personalised Treatment , 2021 .

[21]  Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of Radioactive Substances Advisory Committee. , 2000, Nuclear medicine communications.